Compare AQST & DPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AQST | DPG |
|---|---|---|
| Founded | 2004 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 504.0M | 525.1M |
| IPO Year | 2007 | 2011 |
| Metric | AQST | DPG |
|---|---|---|
| Price | $4.14 | $14.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 79.1K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,430,000.00 | N/A |
| Revenue This Year | $10.08 | N/A |
| Revenue Next Year | $49.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.77 | N/A |
| 52 Week Low | $2.38 | $12.02 |
| 52 Week High | $7.55 | $15.15 |
| Indicator | AQST | DPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.82 | 52.80 |
| Support Level | $4.02 | $14.37 |
| Resistance Level | $4.38 | $14.73 |
| Average True Range (ATR) | 0.22 | 0.19 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 14.90 | 63.86 |
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund, and its objective is to seek total return, derived mainly from a high level of current income, with an emphasis on providing tax-advantaged dividend income and growth in current income, and secondarily from capital appreciation.